SCHEMBL7049809

SCHEMBL7049809

CCCC(CP(=O)(O)CSc1ccc2ccccc2n1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 6/20 0.48
RXFP1 Q9HBX9 5/20 0.48
KDM4E B2RXH2 2/20 0.48
MMP1 P03956 2/20 0.46
MMP2 P08253 2/20 0.46
MMP3 P08254 2/20 0.46
MMP7 P09237 2/20 0.46
MMP8 P22894 2/20 0.46
NPSR1 Q6W5P4 4/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPK10 P53779 2/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
HPGD P15428 1/20 0.39
USP9X Q93008 1/20 0.38
KCNK2 O95069 1/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7048091 0.88 RXFP1 (0.47) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL7048991 0.87 MMP1 (0.52) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL7050067 0.86 RXFP1 (0.45) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL7051208 0.85 RXFP1 (0.49) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL7051220 0.81 PPARG (0.45)
SCHEMBL7047072 0.80 RXFP1 (0.44) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL7051219 0.80 FOLH1 (0.41) MMP1
SCHEMBL7050257 0.77 MEN1 (0.38) MMP1ALDH1A1KMT2AMEN1HPGD
SCHEMBL7244226 0.77 PRNP (0.53) PRNPRXFP1KDM4EMMP1MMP2
SCHEMBL13024376 0.75 PRNP (0.51) PRNPRXFP1KDM4ENPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
EP-0726903-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1996-08-21 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed
WO-1995012603-A1 MATRIX METALLOPROTEASE INHIBITORS________________________________ SYNTEX (U.S.A.) INC. (US) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PRNP 327/4885RXFP1 738/4885KDM4E 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.